CLINICAL_TRIALS
trial_result
· 2022-09-22
Clinical Trial Update: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer [Phase 2]
Summary
Phase 2 trial of abemaciclib for RB-positive, triple-negative metastatic breast cancer was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-09-22